Celgene (CELG) Tops Q4 EPS by 2c, Offers FY17 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Celgene (CELG) PT Raised to $147 at Jefferies; Sees Best-in-Class Medium-Term Growth
January 27, 2017 8:43 AM ESTJefferies raised its price target on Celgene (NASDAQ: CELG) to $147.00 (from $142.00) while maintaining a Buy rating.
Analyst Brian Abrahams commented, "Though updates were mostly incremental given recent pre-reporting, the review of sales dynamics, 2017 guidance, and pipeline progress reaffirms our expectation for best-in-class... More
Celgene (CELG) PT Raised to $148 at Oppenheimer
January 26, 2017 3:32 PM ESTOppenheimer analyst Leah Rush Cann raised her price target on Celgene (NASDAQ: CELG) to $148.00 (from $141.00) while maintaining a Outperform rating.
Rush Cann commented, "Celgene reported a strong quarter and year-end that was in line with expectations. The outlook for Celgenes clinical... More
